^
    Back
    Association details:
    Biomarker:Chr t(15;17)
    Cancer:Acute Promyelocytic Leukemia
    Drug:arsenic trioxide (Apoptosis stimulant)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    10/20/2020
    Excerpt:
    TRISENOX is an arsenical indicated...For induction of remission and consolidation in patients with APL who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    10/20/2020
    Excerpt:
    TRISENOX is an arsenical indicated:...In combination with tretinoin for treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    N Engl J Med
    Title:

    Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia

    Published date:
    07/11/2013
    Excerpt:
    Eligible patients were 18 to 71 years of age with newly diagnosed APL...demonstration of the t(15;17) translocation by means of conventional karyotyping or fluorescence in situ hybridization (FISH)...Patients were randomly assigned to receive ATRA plus arsenic trioxide...Hematologic complete remission was achieved in all 77 patients in the ATRA–arsenic trioxide group (100%) and in 75 of the 79 patients in the ATRA–chemotherapy group (95%) (P=0.12).
    DOI:
    10.1056/NEJMoa1300874
    Trial ID:
    APL0406
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Phase III Trial in Acute Promyelocytic Leukemia Patients

    Excerpt:
    ...- Serum creatinine ≤ 3.0 mg/dL (≤ 260 µmol/L) The confirmation of diagnosis at genetic level (microspeckled PML nuclear distribution by PGM3 monoclonal antibody and/or PML/RARa fusion by RT-PCR and/or demonstration of t(15;17) by karyotyping) will be mandatory for patient eligibility....
    Trial ID:
    APL0406
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    Retrospective study of realgar-indigo naturalis formula in the treatment of patients with relapsed and arsenic trioxide-resistant acute promyelocytic leukemia

    Excerpt:
    ...Demonstration of PML-RARα fusion transcripts by RT-PCR or cytogenetic demonstration of t(15;17)(q22;q12); 3. ...
    Trial ID:
    ChiCTR2200065047